促红细胞生成素对肝癌生长影响的临床研究

doi:10.3969/j.issn.1000-8535.2019.01.009

广州医药 ›› 2019, Vol. 50 ›› Issue (1): 36-40.DOI: 10.3969/j.issn.1000-8535.2019.01.009

促红细胞生成素对肝癌生长影响的临床研究

李瑞芹, 郑海涛, 苏伟民, 陈凤燕

普宁市人民医院（普宁 515300)

收稿日期:2018-08-07 出版日期:2019-01-20 发布日期:2021-12-21
基金资助:
广东省揭阳市科技局卫生医疗项目（2017YL036）

Clinical study on the effect of erythropoietin on the growth of liver cancer

LI Ruiqing, ZHEN Haitao, SU Weiming, CHEN Fengyan

Puning People's Hospital, Puning 515300 China

Received:2018-08-07 Online:2019-01-20 Published:2021-12-21

摘要/Abstract

摘要： 目的分析促红细胞生成素（EPO）及促红细胞生成素受体（EPOR）在肝细胞癌（NCC）以及正常组织中的表达规律,以及它们和肝细胞癌微血管密度（MVD）之间的关系。方法选取我院手术切除的肝细胞肝癌的标本30例,取肿瘤边缘2.0 cm的肝组织作为对照,同时取正常肝脏组织10例做为阴性对照。利用酶联免疫吸附实验（ELISA）检测各组织中EPO及EPOR表达水平,利用免疫组织化学方法染色检测微血管密度（MVD）。对比癌组织和癌旁组织EPO、EPOR及MVD差异,分析NCC中EPO、EPOR、MVD与肿瘤病理特征的关系,分析EPO、EPOR表达水平与MVD之间的关系。结果 HCC组织中,EPR、EPOR、MVD均高于癌旁组织和正常组织,差异有统计学意义（P<0.001）,EPR、EPOR、MVD在癌旁组织和正常组织中,差异无统计学意义（P>0.05）。肿瘤大小>5 cm、存在包膜侵犯、存在远处转移以及高中分化的HCC中,EPR、EPOR、MVD水平高于肿瘤大小≤5 cm、无包膜侵犯、无远处转移以及低分化的水平,差异有统计学意义（P<0.05）。Person相关分析结果显示,EPO表达水平与MVD的相关系数r=0.651（P<0.001）,EPOR表达水平与MVD的相关系数r=0.620（P<0.001）。结论 EPO、EPOR、MVD在HCC中呈现高水平,且与肿瘤大小、局部侵犯、远处转移及分化程度有关,其机制可能与EPO、EPOR增加MVD有关。

关键词: 促红细胞生成素, 促红细胞生成素受体, 肝癌, 肿瘤生长

Abstract: Objective To analyze the expression of erythropoietin （EPO） and erythropoietin receptor （EPOR） in hepatocellular carcinoma （NCC） and normal tissues,and their relationship with hepatocyte microvessel density （MVD）. Methods Thirty specimens of hepatocellular carcinoma hepatectomy were selected from our hospital. The liver tissue at the edge of the tumor was taken as a control,and 10 cases of normal liver tissue were used as a negative control. The expression levels of EPO and EPOR in each tissues were detected by enzyme-linked immunosorbent assay （ELISA）,and microvessel density （MVD） was detected by immunohistochemistry. The differences of EPO,EPOR and MVD between each tissues were compared. The relationship between EPO,EPOR,MVD and tumor pathological features in NCC was analyzed. The relationship between EPO and EPOR expression levels and MVD was analyzed. Results In HCC tissues,EPR,EPOR and MVD were higher than those in adjacent tissues and normal tissues. The difference was statistical difference （P<0.001）. EPR,EPOR and MVD were not statistically significant in adjacent tissues and normal tissues. P>0.05）. The levels of EPR,EPOR,and MVD in tumors with tumor size >5 cm,invasion of the capsule,distant metastasis,and high-differentiation were higher than those of tumor size ≤ 5 cm,no capsule invasion,no distant metastasis,and poor differentiation. The difference was statistical difference （P < 0.05）. Person correlation analysis showed that the correlation coefficient between EPO expression level and MVD was r=0.651 （P<0.001）,and the correlation coefficient between EPOR expression level and MVD was r=0.620 （P<0.001）. Conclusion EPO,EPOR and MVD are highly expressed in HCC,and are related to tumor size,local invasion,distant metastasis and differentiation. The mechanism may be related to EPO and EPOR increasing MVD.

Key words: Erythropoietin, Erythropoietin receptor, Liver cancer, Tumor growth

李瑞芹, 郑海涛, 苏伟民, 陈凤燕. 促红细胞生成素对肝癌生长影响的临床研究[J]. 广州医药, 2019, 50(1): 36-40.

LI Ruiqing, ZHEN Haitao, SU Weiming, CHEN Fengyan. Clinical study on the effect of erythropoietin on the growth of liver cancer[J]. Guangzhou Medical Journal, 2019, 50(1): 36-40.

参考文献

[1] BRUIX J,GORES G J,MAZZAFERRO V.Hepatocellular carcinoma:clinical frontiers and perspectives[J]. Gut,2014,63(5):844-855.
[2] MOCCIA F,DRAGONI S,POLETTO V,et al.Orai1 and transient receptor potential channels as novel molecular targets to impair tumor neovascularization in renal cell carcinoma and other malignancies[J]. Anticancer Agents Med Chem,2014,14(2):296-312.
[3] ALEMPIJEVIC T,ZEC S,NIKOLIC V,et al.Erythropoietin in predicting prognosis in patients with acute-on-chronic liver failure[J]. J Gastrointest Liver Dis,2016,25(4):54-72.
[4] VÅTSVEEN T K,SPONAAS A M,TIAN E,et al. Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro[J]. J Hematol oncol,2016,9(1):75-79.
[5] MURAKAMI K,KASAJIMA A,KAWAGISHI N,et al.Microvessel density in hepatocellular carcinoma:prognostic significance and review of the previous published work[J]. Hepatol Res,2015,45(12):1185-1194.
[6] WEIDNER N.Intratumor microvessel density as a prognostic factor in cancer[J]. Am J pathol,1995,147(1):9-11.
[7] TANIGAWA N,AMAYA H,MATSUMURA M,et al.Tumor angiogenesis and mode of metastasis in patients with colorectal cancer[J]. Cancer Res,1997,57(6):1043-1046.
[8] MERKLE R,STEIERT B,SALOPIATA F,et al.Comprehensive modelling of multiple cell types reveals differences in Epo receptor signaling in primary erythroid and lung cancer cells[J]. Pneumol,2015,69(07):A76-A79.
[9] CHAI H T,YIP H K,SUN C K,et al.AG490 suppresses EPO-mediated activation of JAK2-STAT but enhances blood flow recovery in rats with critical limb ischemia[J]. J Inflamm,2016,13(1):18-23.
[10] THOMAS S J,SNOWDEN J A,ZEIDLER M P,et al.The role of JAK/STAT signalling in the pathogenesis,prognosis and treatment of solid tumours[J]. Br J Cancer,2015,113(3):365-369.
[11] MUTO J,SHIRABE K,SUGIMACHI K,et al.Review of angiogenesis in hepatocellular carcinoma[J]. Hepatol Res,2015,45(1):1-9.
[12] QU Z,JIANG Y,XU M,et al.Correlation of adrenomedullin with the erythropoietin receptor and microvessel density in hepatocellular carcinoma[J]. Arch Med Sci:AMS,2015,11(5):978-983.
[13] TOPHURIA D,MATOSHVILI M.Activity after liver resection[J]. Dig Surg,2016,33(1):1-232.

促红细胞生成素对肝癌生长影响的临床研究

Clinical study on the effect of erythropoietin on the growth of liver cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 7

编辑推荐

Metrics

本文评价

[1]	胡志文, 萧淑宜, 格桑卓玛, 金海, 董燕, 柳建华. 微泡超声空化在增强微波消融对肝脏肿瘤的热消融效应中的价值[J]. 广州医药, 2021, 52(1): 43-48.
[2]	李柱, 廖信芳, 吕海钠. 超声引导下射频消融术治疗肝癌术后局部复发因素分析[J]. 广州医药, 2020, 51(6): 79-82.
[3]	林晓纯, 林坤鹏, 林纯旋. 贝伐单抗联合肝动脉化疗栓塞治疗原发性肝癌的 Meta分析[J]. 广州医药, 2020, 51(3): 86-92.
[4]	刘霞, 方喜生, 翁成荫, 伍勇, 毛海波, 李宝秀, 王丽娜, 刘国龙. 原发性肝癌患者循环肿瘤细胞检测及其与术后复发转移的关系[J]. 广州医药, 2020, 51(2): 36-39.
[5]	沈玲, 杨秀丽, 亚国伟, 胡孟达. 小剂量阿帕替尼联合TACE治疗晚期肝癌临床观察[J]. 广州医药, 2019, 50(2): 72-75.
[6]	矫元君, 尹耀新. miRNAs在肝细胞肝癌发展过程中的研究进展[J]. 广州医药, 2018, 49(2): 123-126.
[7]	林华赋, 刘德昭, 程芳. 低中心静脉压在肝癌患者肝切除手术中的应用研究[J]. 广州医药, 2018, 49(2): 58-62.